Accelerate Diagnostics Inc (AXDX) Expected to Announce Earnings of -$0.43 Per Share

Brokerages expect Accelerate Diagnostics Inc (NASDAQ:AXDX) to report earnings of ($0.43) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Accelerate Diagnostics’ earnings, with the lowest EPS estimate coming in at ($0.45) and the highest estimate coming in at ($0.41). Accelerate Diagnostics posted earnings per share of ($0.37) during the same quarter last year, which would indicate a negative year over year growth rate of 16.2%. The company is scheduled to report its next earnings report on Wednesday, May 8th.

On average, analysts expect that Accelerate Diagnostics will report full-year earnings of ($1.79) per share for the current financial year, with EPS estimates ranging from ($1.87) to ($1.72). For the next fiscal year, analysts expect that the company will report earnings of ($1.83) per share, with EPS estimates ranging from ($2.00) to ($1.65). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that follow Accelerate Diagnostics.

Accelerate Diagnostics (NASDAQ:AXDX) last released its earnings results on Tuesday, February 19th. The medical research company reported ($0.41) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.41). The firm had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $1.83 million. Accelerate Diagnostics had a negative return on equity of 105.12% and a negative net margin of 1,564.01%.



A number of brokerages have recently issued reports on AXDX. BidaskClub upgraded Accelerate Diagnostics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 5th. Zacks Investment Research upgraded Accelerate Diagnostics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research note on Friday, December 21st. Finally, Piper Jaffray Companies upped their price objective on Accelerate Diagnostics to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 20th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. Accelerate Diagnostics presently has a consensus rating of “Hold” and a consensus target price of $18.75.

Shares of Accelerate Diagnostics stock opened at $18.65 on Friday. Accelerate Diagnostics has a 12-month low of $10.23 and a 12-month high of $25.35. The company has a market cap of $1.05 billion, a PE ratio of -11.51 and a beta of 3.17. The company has a current ratio of 22.88, a quick ratio of 21.89 and a debt-to-equity ratio of 2.09.

Institutional investors have recently made changes to their positions in the company. Legal & General Group Plc raised its stake in shares of Accelerate Diagnostics by 45.2% during the 4th quarter. Legal & General Group Plc now owns 5,995 shares of the medical research company’s stock worth $69,000 after purchasing an additional 1,866 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its holdings in shares of Accelerate Diagnostics by 331.4% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,727 shares of the medical research company’s stock worth $100,000 after acquiring an additional 6,704 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Accelerate Diagnostics by 82.2% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,556 shares of the medical research company’s stock worth $159,000 after acquiring an additional 6,114 shares during the last quarter. Man Group plc acquired a new position in shares of Accelerate Diagnostics during the 3rd quarter worth approximately $313,000. Finally, MetLife Investment Advisors LLC increased its holdings in shares of Accelerate Diagnostics by 59.1% during the 3rd quarter. MetLife Investment Advisors LLC now owns 18,052 shares of the medical research company’s stock worth $414,000 after acquiring an additional 6,704 shares during the last quarter. Institutional investors own 48.90% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Featured Story: Asset Allocation

Get a free copy of the Zacks research report on Accelerate Diagnostics (AXDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.